Sarepta Therapeutics obtained exclusive, global rights to the University of Western Australia's patent portfolio of investigational drug therapies for Duchenne muscular dystrophy. The firm will use the patents to develop exon-skipping treatments for DMD. The university will get as much as $7.1 million in upfront and milestone fees plus sales royalties.

Related Summaries